Business Wire

SamanTree Medical Achieves FDA Clearance for Histolog® Scanner, Ushering in a New Era of Tissue Imaging in the U.S.

13.9.2024 09:00:00 EEST | Business Wire | Press release

Share

SamanTree Medical, a leader in innovative surgical imaging solutions, today announced that it has received FDA 510(k) clearance of its Histolog® Scanner for imaging of the internal microstructure of tissues including, but not limited to, the identification of cells, vessels and their organization or architecture. This groundbreaking Swiss made device is designed to provide real-time, highresolution imaging of fresh tissue surfaces, offering surgeons and pathologists this information for excised tissue.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240912995435/en/

The Histolog Scanner in use for rapid visualization of fresh tissue microstructures. (Photo: SamanTree Medical)

The Histolog® Scanner enables real-time, ultra-fast confocal microscopy, allowing for the immediate imaging of resected tissues. This advancement aims to enable physicians to improve their efficiency.

“We are thrilled to introduce the Histolog® Scanner to the U.S. market,” said Dr. Charles Carignan, Executive Chairman of SamanTree Medical. “This FDA clearance is a significant milestone for the company. The ability of the Histolog® Scanner to produce real-time imaging of the internal microstructure of tissues provides surgeons and pathologists with immediate, actionable information.”

Prof. Dr. Alex Mottrie, Head of the Urological Department OLV Hospital, Aalst, Belgium and CEO of ORSI Academy, Ghent, Belgium, commented on the impact of this new technology: “The Histolog® Scanner represents cutting-edge technology in imaging of freshly excised tissue. Its ability to provide high-resolution, real-time images allows us to make more informed decisions.”

Prof. Dr. Ari D. Brooks, Director of Endocrine and Oncologic Surgery, Pennsylvania Hospital, Philadelphia, PA said “The Histolog technology has the potential to significantly reduce the cost, resources and delays associated with the current lack of real-time high-resolution imaging”. Prof Dr. Douglas Scherr, Clinical Director of Urologic Oncology at the Weill Medical College of Cornell University said “Providing imaging data at this resolution has the potential to aid in patient care. In our practice and across Urology, as a field, we are facing limitations in the ability to provide timely decisions to our patients. We will count on the Histolog Scanner to provide us with the ability to image the tissues’ microstructures in real-time and to enable us to make immediate decisions.”

The FDA clearance of the Histolog® Scanner marks a crucial moment in SamanTree Medical’s mission to expand its innovative imaging solutions globally. With this clearance, SamanTree is set to accelerate its U.S. market entry, ensuring that more healthcare providers can leverage the benefits of this cutting-edge technology.

About SamanTree Medical

SamanTree Medical is committed to enhancing clinical outcomes through the development of advanced imaging technologies. The Histolog® Scanner, now FDA-cleared, offers realtime, high-resolution imaging of excised tissue surfaces, providing physicians with this information for immediate assessments. Following the initial commercialization in Europe, the Histolog® Scanner is poised to make a significant impact in the U.S. healthcare market.

For more information, visit www.samantree.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240912995435/en/

Contacts

Contact Information
Olivier Delporte
CEO, SamanTree Medical
info@samantree.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer8.10.2026 14:30:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and Evamplix® (balstilimab, BAL), each approved for use in combination with the other for the treatment of adult patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases who have previously received available standard therapies. These are the first marketing authorizations for either medicine anywhere in the world. The approvals are expected to benefit patients in Armenia as well as patients who travel to Armenia for treatment under the care of Armenian oncologists. Botensilimab is a multifunctional, Fc-enhanced anti-CTLA-4 antibody designed to activate innate and adaptive antitumor immune responses, including in tumors that have historically responded poorly to conventional immunotherapy. Balstilimab is an anti-PD-1 antibody de

NTT DOCOMO BUSINESS and Classiq Enter Strategic Business Partnership to Accelerate Enterprise Adoption of Quantum Computing8.10.2026 14:00:00 EEST | Press release

NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) and Classiq Technologies G.K., the Japanese subsidiary of Classiq Technologies Ltd., today announced a memorandum of understanding establishing a strategic business partnership aimed at accelerating enterprise adoption of quantum computing1 in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007985427/en/ NTT DOCOMO BUSINESS and Classiq logos Under the partnership, NTT DOCOMO BUSINESS will propose and sell the Classiq quantum software development platform and work with Classiq to help enterprises identify, develop and validate quantum computing use cases. Classiq will provide the platform, along with expertise and technical support related to quantum algorithms and quantum software technologies. The two companies will combine Classiq’s quantum software technology with NTT DOCOMO BUSINESS’s experience bringing advanced technologies into real-world ent

NIQ Reaches Key Milestone in Acquisition of The U Group, Strengthening Trusted Intelligence and The Full View™8.10.2026 13:45:00 EEST | Press release

NielsenIQ (NYSE: NIQ) today announced that its wholly-owned Australian subsidiary, Nielsen Connect Australia Pty Ltd (NIQ Australia), has exceeded the 90% shareholder acceptance threshold under its off-market takeover bid for The U Group & Co Limited (The U Group), an Australian-based company specializing in consumer participation, receipt intelligence, and AI-powered data processing capabilities. Achieving the acceptance threshold represents a significant milestone in the transaction process and enables NIQ Australia to proceed with the compulsory acquisition of the remaining shares in The U Group in accordance with applicable Australian law. Building on a successful five-year partnership, the transaction strengthens NIQ's trusted intelligence foundation and advances its strategy to deliver the industry's most complete understanding of consumer buying behavior. By bringing together NIQ's measurement, analytics, and consumer intelligence capabilities with The U Group's consumer partici

Movado Group, Inc. Enters Into Agreement to Sell Majority Interest in EBEL8.10.2026 13:45:00 EEST | Press release

Movado Group, Inc. (NYSE: MOV) today announced that it has entered into a binding agreement to sell a 95% interest in its EBEL brand for $66.5 million to a strategic buyer group led by Montres Journe SA (“Montres Journe”), a Geneva-based luxury watch manufacturer, with the participation of Chanel (“Chanel”), the luxury house, and Pierre Jacques, a renowned figure in the Swiss watch industry, who will serve as Chief Executive Officer of EBEL. The transaction is subject to customary adjustments and closing conditions with Movado Group retaining a 5% interest in the business. Founded in Switzerland in 1911, EBEL is a premium luxury watch brand known for its distinctive design, craftsmanship and rich heritage. This strategic sale allows Movado Group to sharpen its focus on its core accessible luxury and fashion watch and jewelry portfolio, while providing EBEL with a new ownership platform specifically positioned to support the brand’s long-term development. With the expertise and capital

Network X 2026 Brings Europe’s Telecom Leaders Together in Vienna to Define the Future of Connectivity8.10.2026 13:42:00 EEST | Press release

Network X 2026 unites the telecommunications industry’s most influential executives and technology leaders at VIECON Vienna from 13-15 October, with a high-powered Headliners programme focused on the forces reshaping the future of connectivity. Across three days, CEOs, CTOs, technology chiefs, regulators and industry experts from leading operators and technology organisations will examine how artificial intelligence, network sovereignty, broadband networks, 6G, cloud, infrastructure investment and new business models are changing the role of the telecom operator. The programme features senior executives from A1 Group, Swisscom, Drei Austria, A1 Austria, Orange, Deutsche Telekom, Vodafone Group, Kyivstar, 4iG Telecommunications Holding, Yettel Bulgaria, Play Poland, Orange Slovensko, NGMN Alliance and other major players across the global connectivity ecosystem. Industry Leaders Take the Stage Network X 2026 will feature a series of keynote presentations, fireside conversations and high

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye